The upcoming earnings report for Merck & Co., Inc. is scheduled for Wednesday, April 29th. Analysts estimate an earnings per share (EPS) of -1.47384.
Merck & Co., Inc. is currently trading at $110.52, with a price increase of 29 cents (0.263%) from the previous close of $110.23. The trading volume is $3 million, representing a volume increase of 27.76% compared to the average.
The latest quarterly earnings call for Merck & Co., Inc. took place on Monday, February 2nd, with a consensus estimated EPS of 2.04. Further revenue and profit margin details are not available for this period.
Merck & Co., Inc. offers a forward dividend yield of 3.08%. The company distributed 85 cents per share in the most recent quarter, showing a year-over-year increase of 5.1282 cents. The trailing twelve months dividend per share stands at $3.32.
The company reported a free cash flow of $1.82 billion. Notable figures include debt repayment of $-7.85 billion and net change in cash of $-3.51 billion.
In the last reported period, Merck & Co., Inc. generated $16.4 billion in revenue, resulting in a gross profit of $15.20 billion. The net income for the period was $2.96 billion, with an earnings per share (EPS) and diluted EPS of $1.19.
Key ratios for Merck & Co., Inc. include a gross profit margin of 92.71%, net profit margin of 18.07%, and a return on equity of 5.63%.
The company's total assets amount to $136.87 billion, with total liabilities standing at $84.20 billion. Merck & Co., Inc. holds $14.56 billion in cash and cash equivalents.
This article provides a snapshot of Merck & Co., Inc.'s financial status and performance as of the current trading session.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.